Early Type 2 Diabetes Treatment Intensification with Glucagon-Like Peptide-1 Receptor Agonists in Primary Care: An Australian Perspective on Guidelines and the Global Evidence
Early and intensive management of type 2 diabetes has been shown to delay disease progression, reduce the risk of cardiorenal complications and prolong time to treatment failure. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are being increasingly recognized for their potential in early disease management, with recent guideline updates recommending second-line use of this injectable drug class…